4.6 Article

Deletion of monoamine oxidase A in a prostate cancer model enhances anti-tumor immunity through reduced immune suppression

Related references

Note: Only part of the references are listed.
Article Oncology

Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer

Mitchell E. Gross et al.

Summary: Phenelzine showed efficacy in patients with biochemical recurrent castrate-sensitive prostate cancer, with mild treatment-related toxicities observed in most patients and rare significant and reversible cardiovascular toxicities. Treatment reduced anxiety symptoms significantly, but did not change depressive symptoms. Therapies targeting MAOA may provide a new avenue for treating recurrent prostate cancer patients.

PROSTATE CANCER AND PROSTATIC DISEASES (2021)

Article Chemistry, Multidisciplinary

Near-Infrared Monoamine Oxidase Inhibitor Biodistribution in a Glioma Mouse Model

Ronald W. Irwin et al.

Summary: NMI demonstrates good biodistribution and typical fluorescence signals in mice, with superior performance particularly in brain tumors, indicating appropriate dosage range and target organs.

PHARMACEUTICAL RESEARCH (2021)

Article Neurosciences

Near-Infrared MAO A Inhibitor (NMI) Outperformed FDA-Approved Chemotherapeutic Agents in Brain and Other Cancers: A Bioinformatic Analysis of NCI60 Screening Data

Qianhua Feng et al.

Summary: The study demonstrates that NMI is a novel and potent theragnostic drug with unique mechanisms for treating brain, prostate, NSCLC, and other cancers. In vitro efficacy of NMI surpasses that of FDA-approved drugs for CNS cancer, prostate cancer, and NSCLC, showing higher potency in several cancer cell lines compared to others. Pairwise Pearson Correlation Coefficient (PCC) analysis indicates that NMI has a distinct mechanism of action compared to existing anticancer drugs.

BRAIN SCIENCES (2021)

Review Clinical Neurology

Monoamine oxidase isoenzymes: genes, functions and targets for behavior and cancer therapy

Jean C. Shih

JOURNAL OF NEURAL TRANSMISSION (2018)

Editorial Material Clinical Neurology

Introduction to the special issue on monoamine oxidase A and B: eternally enigmatic isoenzymes

Jean Chen Shih et al.

JOURNAL OF NEURAL TRANSMISSION (2018)

Article Oncology

Monoamine oxidase A is highly expressed in classical Hodgkin lymphoma

Pei Chuan Li et al.

JOURNAL OF PATHOLOGY (2017)

Article Chemistry, Multidisciplinary

Monoamine Oxidase A Inhibitor-Near-Infrared Dye Conjugate Reduces Prostate Tumor Growth

Jason Boyang Wu et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)

Article Medicine, Research & Experimental

Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis

Jason Boyang Wu et al.

JOURNAL OF CLINICAL INVESTIGATION (2014)

Article Clinical Neurology

Monoamine oxidase A and A/B knockout mice display autistic-like features

Marco Bortolato et al.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)

Review Pharmacology & Pharmacy

Monoamine oxidase inactivation: From pathophysiology to therapeutics

Marco Bortolato et al.

ADVANCED DRUG DELIVERY REVIEWS (2008)

Review Immunology

Polarized immune responses differentially regulate cancer development

Magnus Johansson et al.

IMMUNOLOGICAL REVIEWS (2008)

Article Multidisciplinary Sciences

A molecular correlate to the Gleason grading system for prostate adenocarcinoma

Lawrence True et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)

Article Immunology

Characterization of CD4+ CTLs ex vivo

V Appay et al.

JOURNAL OF IMMUNOLOGY (2002)

Review Biochemistry & Molecular Biology

The roles of IFNγ in protection against tumor development and cancer immunoediting

H Ikeda et al.

CYTOKINE & GROWTH FACTOR REVIEWS (2002)